| A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity (NCT06854952) | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2025-03-07 |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) (NCT06163430) | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2024-03-26 |
| DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis (NCT05415722) | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2022-06-28 |
| AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NCT04897594) | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2021-05-20 |
| LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) (NCT04328077) | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-06-18 |